ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01559363
Recruitment Status : Active, not recruiting
First Posted : March 21, 2012
Last Update Posted : April 11, 2018
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : July 2019